Synergy CHC Corp. revenue by segment SNYRQ

Synergy CHC Corp. splits its revenue 2 ways in its filings. By operating segments, the largest line in fiscal 2025, which ended Dec 31, 2025 was Nutraceuticals at $29.7 million, 98% of the total. By sales mix, the largest line in fiscal 2025, which ended Dec 31, 2025 was Retail at $22.2 million, 73% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line
FY 2026
Mar 31, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2019
Dec 31, 2019
FY 2018
Dec 31, 2018
FY 2017
Dec 31, 2017
FY 2016
Dec 31, 2016
FY 2015
Dec 31, 2015
FY 2014
Dec 31, 2014
FY 2012
Jul 31, 2013
Revenue
28
30
35
29
34
36
35
13
0
—
Operating segments
Nutraceuticals
—
30
-11.0%
share 97.9%
33
share 95.9%
—
—
—
—
—
—
—
Beverages
—
1
-55.7%
share 2.1%
1
share 4.1%
—
—
—
—
—
—
—
Consumer Goods
—
0
+6.4%
share 0.1%
0
share 0.0%
—
—
—
—
—
—
—
Sales mix
Retail
21
-13.1%
share 74.2%
22
-16.0%
share 73.2%
26
share 76.0%
—
—
—
—
—
—
—
Online
7
-28.1%
share 25.8%
8
-2.7%
share 26.8%
8
share 24.0%
—
—
—
—
—
—
—
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
Medicinal Chemicals & Botanical Products (SIC 2833)
Listed as
SNYRQ (OTC)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
Westbrook, ME
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1562733
Former names
Synergy Strips Corp. (until Aug 6, 2015); Oro Capital Corporation, Inc. (until Apr 24, 2014)

Other Medicinal Chemicals & Botanical Products companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.